A phase II randomized double blinded study of green tea catechins (GTC) vs. placebo in men on active surveillance for prostate cancer: Modulation of biological and clinical intermediate biomarkers.
Lay Description
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance. Green tea catechins may stabilize prostate cancer and lower the chance of prostate growing.
Category
- Cancers and Other Neoplasms
- Mens Health
- Prostate Cancer
- IRB Number
- 20220516HU
- NCT Number
- NCT04597359
- Open to Enrollment
- Not set
Eligibility
- Eligible Ages
- 21 and over
- Eligible Genders
- male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Michael Liss
(210) 567-0548
liss@uthscsa.edu
Regulatory Point of Contact
Benjamin Schleif
(210) 450-1366
schleifb@uthscsa.edu
Principal Investigator
Michael Liss